Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial
Masayuki Tahara, Tomoko Oeda, Kazumasa Okada, Takao Kiriyama, Kazuhide Ochi, Hirofumi Maruyama, Hikoaki Fukaura, Kyoichi Nomura, Yuko Shimizu, Masahiro Mori, Ichiro Nakashima, Tatsuro Misu, Atsushi Umemura, Kenji Yamamoto, Hideyuki Sawada
Topics & Concepts
MedicineRituximabNeuromyelitis opticaPlaceboConcomitantPrednisoloneInternal medicineExpanded Disability Status ScaleClinical trialPediatricsSurgeryMultiple sclerosisImmunologyPathologyAlternative medicineLymphomaMultiple Sclerosis Research StudiesPeripheral Neuropathies and DisordersSpondyloarthritis Studies and Treatments